Biotech Series A: Morphocell Secures $50M to Accelerate the Future of Liver Regeneration
Morphocell, a Montreal-based biotechnology company at the forefront of regenerative medicine, has officially closed its Series A funding at USD 50 million. This landmark financing round positions the company to aggressively scale its liver-regeneration technology, push its clinical roadmap toward human proof-of-concept,
